About the Authors
- John Gatfield
-
* E-mail: john.gatfield@actelion.com
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Celia Mueller Grandjean
-
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Daniel Bur
-
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Martin H. Bolli
-
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Oliver Nayler
-
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
Competing Interests
All authors are employees and shareholders of the funder, Actelion Pharmaceuticals Ltd. Bosentan and macitentan are marketed products of Actelion Pharmaceuticals Ltd, and both compounds are under protection by patents licensed in or held by Actelion Pharmaceuticals Ltd (bosentan: patent family corresponding to EP 526708 (F. Hoffmann-La Roche AG); macitentan: patent family corresponding to WO 02/053557 (Actelion Pharmaceuticals Ltd)). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JG DB MB CMG. Performed the experiments: CMG MB DB. Analyzed the data: CMG JG MB ON DB. Wrote the paper: JG DB ON MB.